scholarly journals The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

2020 ◽  
pp. 3-8
Author(s):  
M. Mostafi ◽  
M. Jabin ◽  
Z. Chowdhury ◽  
M.U. Khondoker ◽  
S.M. Ali ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Side Effects ◽  
End Stage Renal Disease ◽  
Low Dose ◽  
Hcv Infection ◽  
Full Dose ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to their use in developing countries. Aim. This study aimed to evaluate the efficacy of low dose Sofosbuvir along with Daclatasvir in the management of HCV infection in end-stage renal disease (ESRD) patients. Methods. A total of 82 HCV positive patients on ESRD were included in this study. The patients were observed for six months without antiviral drugs. Patients who remained seropositive were divided into two groups. The first group included 26 (37%) patients who were treated with half-dose Sofosbuvir 200 mg and Daclatasvir 60 mg and the second group consisted of 44 (63%) patients who have been treated with full-dose Sofosbuvir 400 mg and Velpatasvir 100 mg irrespective of HCV infection genotype for 12 weeks also. Results. 12 (14%) patients became seronegative spontaneously. All patients (100%) of both groups achieved sustained virological response with undetectable HCV RNA in 12 weeks of the treatment. There were nonsignificant gastrointestinal side effects in the full dose Sofosbuvir group. All patients tolerated the DAAs well. No patient discontinued antiviral therapy due to side effects Conclusion. In this study, the spontaneous seroconversion of HCV was 14%. Low-dose Sofosbuvir along with Daclatasvir was safe and as effective as full-dose Sofosbuvir and Velpatasvir in the treatment of HCV in ESRD patients. Low-dose Sofosbuvir regimen can be recommended for HCV infection treatment in ESRD patients.

scholarly journals Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection

2020 ◽  
Vol 14 (05) ◽  
pp. 519-526
Author(s):  
Ruzica Lukic ◽  
Maja Cupic ◽  
Nevena Gajovic ◽  
Milena Jurisevic ◽  
Zeljko Mijailovic ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hcv Infection ◽  
Hepatitis C Infection ◽  
Healthy Control ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Introduction: Hepatitis C Virus (HCV) is the leading cause of chronic liver disease and is a serious global health problem. Hepatitis C infection is highly prevalent in patients with end stage renal disease (ESRD), due to frequent exposure to blood and blood products, nosocomial transmission of HCV, and prolong hemodialysis duration. The aim of the study was to evaluate the influence of IL-33/ST2 signaling pathway on severity of the liver disease in ESRD HCV+ patients. Methodology: Blood samples from patients with end stage renal disease (ESRD) and hepatitis C infection (HCV), 20 patients with HCV infection, 20 patients with ESRD and 20 healthy control donor patients were taken for the examination of biochemical parameters, for the determination of the serum cytokine concentration, and for the molecular diagnostics of HCV. Results: Systemic sST2 positively correlated with serum level of urea and creatinine, respectively. Serum sST2 was significantly increased in ESRD HCV+ patients in comparison to HCV+ group. sST2/IL-1, sST2/IL-4 and sST2/IL-23 ratios were significantly increased in serum of ESRD HCV+ patients in comparison to HCV+ patients. Significantly higher systemic level of sST2 and sST2/IL-1 and sST2/IL-4 ratios were measured in ESRD patients compared to non-ESRD patients. Conclusion: These results suggested that elevated level sST2, as the consequence of renal failure, causes less destruction of liver in HCV infection.

HLA status and hepatitis C virus (HCV) infection in caucasians with end-stage renal disease (ESRD)

1996 ◽  
Vol 47 (1-2) ◽  
pp. 122
Author(s):  
W. Endres ◽  
D.-F. Chen ◽  
V. Kliem ◽  
H.L. Tillmann ◽  
R. Brunkhorst ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hcv Infection ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Hepatitis ‘B’ and Hepatitis ‘C’ Virus Infection in Haemodialysis Patients

2015 ◽  
Vol 10 (2) ◽  
pp. 66-70
Author(s):  
AKM Mijanur Rahman
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hcv Infection ◽  
Military Hospital ◽  
Strict Adherence ◽  
Stage Renal Disease ◽  
End Stage

Introduction: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection are important causes of morbidity and mortality amongst haemodialysis (HD) patients.Objective: Study was conducted to investigate clinical, laboratory parameters of HCV and HBV infection at nephrology and dialysis centre, Combined Military Hospital, Dhaka, Bangladesh.Methods: It was an cross-sectional study. One hundred and twenty one end stage renal disease (ESRD) patients on maintenance HD, 88 male, 33 female, mean age 51.88 years (range 14–85 years) were included in this study. Clinical and laboratory data such as age, sex aetiology of End Stage Renal Disease (ESRD), HBsAg and anti HCV, HBeAg, PCR for HCV RNA, serum bilirubin, ALT, AST, albumin were examined.Results: The t–test and Chi-Square Tests were used to analyse the significance of the results. Among HD patients HBsAg and anti HCV prevalence rate was 9.1% and 27.3% respectively. Diabetes mellitus and hypertension were common causes of ESRD.Conclusion: Prevalence of HBV and HCV infection is quite high in our HD patients, data emphasise need for strict adherence to infection control, barrier precaution and preventive behaviours.Journal of Armed Forces Medical College Bangladesh Vol.10(2) 2014

scholarly journals SP315ARCHITECT HEPATITIS C VIRUS (HCV) CORE ANTIGEN TEST: A HCV RNA SCREENING ALTERNATIVE IN END-STAGE RENAL DISEASE (ESRD) AND HEMODIALYSIS PATIENTS?

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i450-i450
Author(s):  
Rita Valério Alves ◽  
Rita Abrantes ◽  
Hernâni Gonçalves ◽  
Maria Leonor Gonçalves ◽  
Karina Lopes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients

2014 ◽  
Vol 20 (3) ◽  
pp. 175 ◽  
Author(s):  
Serkan Ocal ◽  
Haldun Selcuk ◽  
Murat Korkmaz ◽  
Reskan Altun ◽  
AbdullahE. Yildirim ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Virus Clearance ◽  
Stage Renal Disease ◽  
End Stage

‘Real-life’ experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease

2018 ◽  
Vol 41 (7) ◽  
pp. 363-370 ◽  
Author(s):  
Rebeca García-Agudo ◽  
Sami Aoufi-Rabih ◽  
Mercedes Salgueira-Lazo ◽  
Carmen González-Corvillo ◽  
Fabrizio Fabrizi
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
End Stage Renal Disease ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Stage Renal Disease ◽  
Direct Acting ◽  
End Stage ◽  
Direct Acting Antiviral Agents

Background and Aims: The advent of direct-acting antiviral agents promises to change the management of hepatitis C in patients with end-stage renal disease, a patient group where the treatment of hepatitis C was historically challenging. We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a ‘real-world’ group of patients with end-stage renal disease. Methods: We performed a single-arm, multi-centre study in a cohort (n=30) of patients with advanced chronic kidney disease (mostly on dialysis) who underwent antiviral therapy with direct-acting antiviral agents. The primary end-point was sustained virologic response (serum hepatitis C virus RNA < 15 mIU/mL, 12 weeks after treatment ended). We collected data on on-treatment adverse events, serious adverse events and laboratory abnormalities. Results: In total, 23 (77%) and 7 (23%) patients underwent regular dialysis and had chronic kidney disease at pre-dialysis stage, respectively. Six regimens were adopted: elbasvir/grazoprevir ( n = 6), ledipasvir/sofosbuvir ± ribavirin ( n = 4), PrOD regimens ± ribavirin ( n = 10), simeprevir + daclatasvir ( n = 3), sofosbuvir + daclatasvir ± ribavirin ( n = 3), sofosbuvir + ribavirin ( n = 4). The SVR12 rate was 90% (95% confidence interval, 74%; 96%). A total of 27 (90%) patients achieved SVR12; there were three virologic failures – two were non-responders and one had a viral breakthrough while on therapy. Adverse events occurred in 53% (16/30) (95% confidence interval, 0.39; 0.73) of patients and were managed clinically without discontinuation of therapy or hospitalization. The most common adverse event was anaemia ( n = 12) that required blood transfusions in seven individuals; deterioration of kidney function occurred in one (14%). Conclusion: All-oral, interferon-free therapy with direct-acting antiviral agents for chronic hepatitis C virus in advanced chronic kidney disease was effective and well tolerated in a ‘real-life’ clinical setting. Careful monitoring of haemoglobin and serum creatinine during therapy with direct-acting antiviral agents is suggested. Studies are under way to address whether sustained viral response translates into better survival in this population.

Sign in / Sign up

Export Citation Format

Share Document